Trial Profile

Effects of 150 mcg Aleglitazar on Renal Function in Patients With Type 2 Diabetes and Moderate Renal Impairment, as Compared to Actos®

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 13 Jul 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aleglitazar (Primary) ; Pioglitazone
Indications Type 2 diabetes mellitus
Focus Pharmacodynamics; Therapeutic Use
Acronyms AleNEPHRO
Sponsors Roche

Most Recent Events

25 Jun 2013 Results reporting lipid, glycaemic and insulin parameters presented at the 73rd Annual Scientific Sessions of the American Diabetes Association.
11 Mar 2013 Results with focus on secondary endpoints presented at the 62nd Annual Scientific Session of the American College of Cardiology.
05 Sep 2012 Primary endpoint 'Glomerular-filtration-rate' has been met.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com